Financial Performance & Projections - Axsome reported Net Product Revenue of $150 million in 2Q 2025, a 72% increase compared to $872 million in 2Q 2024 [21] - AUVELITY Net Product Sales reached $1196 million in 2Q 2025, an 84% increase from $650 million in 2Q 2024 [21] - SUNOSI Net Product Revenue was $30 million in 2Q 2025, a 40% increase compared to $221 million in 2Q 2024 [21] - SYMBRAVO Net Product Sales were $04 million in 2Q 2025 [21] - The company estimates a combined peak sales potential of $165 billion across its differentiated portfolio [16] Clinical & Regulatory Milestones - The company commercially launched SYMBRAVO in the US in June 2025 [20] - Positive topline results were achieved from the EMERGE Phase 3 trial of SYMBRAVO in oral CGRP non-responders in 1Q 2025 [20] - Positive topline results were achieved from the FOCUS Phase 3 trial of solriamfetol in ADHD in adults in 1Q 2025 [20] - Topline results were achieved from the PARADIGM Phase 3 trial of solriamfetol in MDD in 1Q 2025 [20] - An sNDA submission for AXS-05 in Alzheimer's disease agitation is expected in 3Q 2025 [20] - An NDA submission for AXS-12 in narcolepsy is expected in 4Q 2025 [20] Market & Pipeline - The company is developing new indications across approved products and has Phase 3 development programs ongoing [13] - The company plans to initiate a Phase 3 trial of solriamfetol in ADHD in pediatric patients in 4Q 2025 [20] - The company plans to initiate a Phase 3 trial of solriamfetol in MDD with EDS in 4Q 2025 [20] - The company plans to initiate a Phase 3 trial of AXS-14 in fibromyalgia in 4Q 2025 [20] - The company plans to initiate a Phase 2/3 trial of AXS-05 in smoking cessation in 4Q 2025 [20]

Financial Performance - Kaspi.kz consolidated revenue increased by 61% YoY to KZT 967501 million in 2Q'25[133] - Kaspi.kz consolidated net income increased by 7% YoY to KZT 258629 million in 2Q'25[133] - The company reiterates its FY 2025 guidance, expecting around 15% net income growth, excluding Türkiye[111] Segment Performance - Payments platform revenue increased by 16% YoY to KZT 161216 million in 2Q'25, with net income up 19% YoY to KZT 105697 million[49, 135] - Marketplace platform revenue increased by 25% YoY to KZT 459088 million in 2Q'25, but net income increased 13% YoY to KZT 70477 million[69, 135] - Fintech platform revenue increased by 21% YoY to KZT 370717 million in 2Q'25, with net income up 8% YoY to KZT 82455 million[88, 135] Key Growth Drivers - E-Grocery GMV grew by 57% YoY in 2Q'25, surpassing 1 million consumers[11, 12] - Advertising revenue on Kaspi.kz increased by 91% YoY in 1H'25[26] - Kaspi Pay TPV from other banks and Alipay increased by 128% since launch[19] Hepsiburada (Türkiye) Performance - Hepsiburada's revenue increased by 23% in 2Q'25[98] - Hepsiburada's EBITDA increased by 42% in 2Q'25[98] - Hepsiburada's net income decreased 39% YoY in 2Q'25[100]

Financial Performance - The company reported revenue of $96.1 million, meeting guidance of approximately $94-97 million[9] - Adjusted EBITDA was $(8.0) million, exceeding guidance of $(13) million[9] - Gross margin reached 53.4%, achieving the target of exceeding 50%+ by 4QFY25[9] - Cash, cash equivalents, and short-term investments totaled $250.8 million as of June 30, 2025[34] Segment Revenue - SynBio revenue was $35.2 million, a 7% year-over-year growth, with approximately 237,000 genes shipped[13] - NGS revenue was $55.3 million, a 27% year-over-year growth, driven by expanded collaborations[16] - Biopharma Solutions revenue was $5.6 million, a 10% year-over-year growth, with $6.2 million in orders[19] FY2025 Guidance - Q4 FY2025 revenue is projected to be approximately $96 to $98 million, with SynBio contributing ~$38 to 39 million, NGS ~$52 to 53 million, and Biopharma ~$6 million[37] - Full-year FY2025 revenue is guided at approximately $374 to $376 million, with SynBio contributing ~$144 to 145 million, NGS ~$207 to 208 million, and Biopharma ~$23 million[37] - Full-year FY2025 Adjusted EBITDA is expected to be ~$(45 to 47M)[37]

Financial Performance - Second quarter 2025 revenues reached €261 million, compared to €129 million in the second quarter of 2024[61] - First half 2025 revenues totaled €444 million, an increase from €316 million in the first half of 2024[61] - The company reported a net loss of €387 million for the second quarter of 2025, compared to a net loss of €808 million for the same period in 2024[61] - Research and Development expenses for the second quarter of 2025 were €509 million, compared to €585 million for the second quarter of 2024[61] - Cash and cash equivalents plus security investments reached approximately €160 billion as of June 30, 2025[12,61] Strategic Collaboration - BioNTech and Bristol Myers Squibb (BMS) entered into a strategic collaboration for BNT3271, with an upfront cash payment of $15 billion expected in Q3 2025[12,62] - The collaboration with BMS includes non-contingent anniversary cash payments of $20 billion from 2026 to 2028[62] - Potential development, regulatory, and commercial milestone cash payments from BMS could reach up to $76 billion[62] Pipeline Development - A Phase 2 study of BNT3271 combined with chemotherapy in 1L ES-SCLC showed an objective response rate (ORR) of 854% and a median overall survival (OS) of 168 months[29] - In a Phase 1b/2a study, BNT3271 monotherapy in 1L NSCLC (EGFR & ALK WT) showed an ORR of 47% and a median PFS of 136 months[34] - A Phase 1/2 study of BNT3271 combined with chemotherapy in 1L TNBC showed an ORR of 738% and a median PFS of 135 months[35]

Financial Performance - Net sales reached $264.7 million, a 12.5% increase year-over-year[13] - Adjusted gross margin improved to 46.9%, up 100 basis points year-over-year[13] - Adjusted EBITDA was $44.4 million, an increase of $9.3 million year-over-year, with an adjusted EBITDA margin of 16.8%, up 190 basis points[13] - Operating cash flow was $33.9 million[13] Operational Efficiency - Logistics costs were 5.7% of net sales, a decrease of 10 basis points year-over-year[13] - Input costs were 28.9% of net sales, a decrease of 90 basis points year-over-year[13] - Quality costs were 2.0% of net sales, a decrease of 70 basis points year-over-year[13] - The company expects to reduce capital spending by at least $100 million in 2025-2026 due to improved output and new technology[17] Retail and Consumer Growth - Total household penetration increased by 11%[13] - Total buy rate increased by 6%[13] - MVP (Most Valuable Pet Parents) household penetration increased by 18%[13] - The company added approximately 1.4 million households year-over-year[25] Guidance - The company updated its net sales growth guidance for FY 2025 to 13-16% year-over-year[62] - Capital expenditures are expected to be approximately $175 million[62] - The company expects to end the year with approximately $250 million in cash and be free cash flow positive in 2026[64]

Financial Performance - Q2 2025 - Loews Corporation's net income was $391 million, or $1.87 per share, compared to $369 million, or $1.67 per share in Q2 2024[14] - The company repurchased 3.0 million shares at a cost of $260 million since March 31, 2025[14] - Book value per share increased to $84.42 as of June 30, 2025, from $79.49 as of December 31, 2024[14] - Dividends from subsidiaries totaled $189 million in Q2 2025[14] - The parent company held $3.4 billion in cash and investments as of June 30, 2025[8, 14] Subsidiary Performance - Q2 2025 - CNA's net income attributable to Loews was $274 million, down from $291 million year-over-year[15, 27] - Boardwalk's net income attributable to Loews increased to $88 million from $70 million year-over-year[15, 30] - Loews Hotels' net income attributable to Loews decreased to $28 million from $35 million year-over-year[15, 32] CNA Financial Highlights - CNA's net written premiums increased to $2.846 billion in Q2 2025 from $2.674 billion in Q2 2024[27] - CNA's underlying combined ratio was 91.7% in Q2 2025, compared to 91.6% in Q2 2024[27] Boardwalk Pipeline Highlights - Boardwalk's operating revenue increased to $534 million in Q2 2025 from $477 million in Q2 2024[30] - Boardwalk's EBITDA was $274 million in Q2 2025, compared to $240 million in Q2 2024[30] Loews Hotels & Co Highlights - Loews Hotels & Co's revenue increased to $254 million in Q2 2025 from $251 million in Q2 2024[32] - Loews Hotels & Co's Adjusted EBITDA was $109 million in Q2 2025, compared to $98 million in Q2 2024[32]

DIGGERS & DEALERS PRESENTATION - AUGUST 2025 For personal use only The Presentation Materials are not investment or financial product advice (nor tax, accounting or legal advice) and are not intended to be used for the basis of making an investment decision. Recipients should obtain their own advice before making any investment decision. Advancing from a single mine +100Koz p.a. gold producer to multi-mine +300Koz p.a. ASX:EMR Presentation Disclaimer DISCLAIMER These presentation materials and the accompany ...

Corporate Overview - Hillgrove Resources has a share price of $0.036 and a market capitalization of $94 million [9] - The company possesses $11 million in cash and $282 million in income tax losses [9] - Freepoint Metals & Concentrates is a major shareholder with 18.9% ownership, followed by Ariadne Australia with 10.3% [9] Production and Cost Metrics (June 2025 Half) - Total tonnes processed reached 669kt with a grade of 0.88% [25] - Copper production amounted to 5,545 tonnes, and payable copper sold was 5,481 tonnes at an average realized price of A$14,232 per tonne [25] - C1 Costs were A$4.68/lb, and All-in Cost excluding Nugent was US$4.10/lb [25] Resource and Reserve - The 2024 Kanmantoo Mineral Resource Estimate is 19.3Mt grading 0.77% Cu and 0.14g/t Au, containing 150kt Cu and 82koz Au [30] - The 2024 Maiden Ore Reserve is 2.8Mt grading 0.91% Cu and 0.15g/t Au, containing 26kt Cu and 14koz Au [30] - Compared to the 2022 Mineral Resource Estimate, there was a 96% increase in contained copper and a 138% increase in contained gold [31] Future Plans - The company plans approximately 20 Km of drilling in 2025 targeting resource expansion, with an early focus on Valentines, Kavanagh, and Nugent [32] - Nugent development aims to reduce mining and processing unit costs by approximately 15-20% [23]

For personal use only Company Update August 2025 Diggers and Dealers, Kalgoorlie This presentation has been prepared without taking into account the investment objectives, financial situation or particular need of any particular person . To the extent permitted by law, no representation or warranty, express or implied, is made as to the accuracy, reliability, completeness or fairness of the information, opinions and conclusions contained in this presentation. To the extent permitted by law, none of Jupiter, ...

Afema Gold Project Rapidly Growing 3.6 Million Ounce Gold Camp Cote d'Ivoire, West Africa For personal use only ASX: TCG TURACOGOLD.COM.AU This presentation has been approved for release to the ASX by the Board of Turaco Gold Ltd August 2025 Disclaimer & Cautionary Statement This Presentation has been prepared as a summary only and does not contain all information about Turaco Gold Limited's ("TCG", "Turaco" or the "Company") assets and liabilities, financial position and performance, profits and losses, pr ...